BioCentury | Oct 6, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of 1.2 million convertible preferred shares at a $7.13 conversion price, which represents a 15%...
BioCentury | Oct 2, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of convertible preferred shares at a $7.13 conversion price, which represents a 15% premium to...
BioCentury | Oct 31, 2016
Company News

NeuroVive, Arbutus Biopharma deal

NeuroVive and Arbutus terminated a 2014 deal that granted OnCore Biopharma Inc. exclusive, worldwide rights to NVP018 to treat HBV infection. OnCore merged with Tekmira Pharmaceuticals Corp. in 2015 to form Arbutus. NeuroVive regained all...
BioCentury | Oct 21, 2016
Company News

Arbutus returns cyclophilin inhibitor to NeuroVive

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) regained rights to NVP018 from Arbutus Biopharma Corp. (NASDAQ:ABUS) as the companies terminated a 2014 deal to develop the compound for HBV. The exclusive, worldwide rights to NVP018 were obtained...
BioCentury | Jul 21, 2015
Company News

Tekmira changing name to Arbutus with HBV focus

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) said it will change its name to Arbutus Biopharma Corp., effective Aug. 3, and will focus on developing HBV therapies. It will form a separate business unit for non-HBV therapies, and...
BioCentury | Jun 22, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/19 cls Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Needham Serge Belanger Upgrade Buy (from hold) 54% $20.02 Belanger also set a $27...
BioCentury | Jun 20, 2015
Clinical News

Tekmira falls on Ebola data

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) lost $1.74 (12%) to $13.28 on Friday on news its TKM-Ebola-Guinea was unlikely to show a therapeutic effect in the Phase II RAPIDE trial to treat Ebola virus infection. As a...
BioCentury | Mar 21, 2015
Financial News

Tekmira raises $151.9M in follow-on

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) raised $151.9 million through the sale of 7.5 million shares at $20.25 in a follow-on underwritten by Leerink; RBC Capital Markets; Nomura; JMP Securities; Wedbush PacGrow; and Lazard. Tekmira proposed the...
BioCentury | Mar 16, 2015
Company News

OnCore Biopharma, Tekmira deal

Tekmira completed its merger with OnCore. The merged company will operate as Tekmira and will continue to trade under the TKMR ticker until a new corporate identity is launched and its ticker symbol is changed...
BioCentury | Jan 19, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/16 cls Depomed Inc. (NASDAQ:DEPO) Roth Capital Partners Scott Henry Upgrade Buy (from neutral) 17% $20.20 Henry also raised his...
Items per page:
1 - 10 of 113
BioCentury | Oct 6, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of 1.2 million convertible preferred shares at a $7.13 conversion price, which represents a 15%...
BioCentury | Oct 2, 2017
Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of convertible preferred shares at a $7.13 conversion price, which represents a 15% premium to...
BioCentury | Oct 31, 2016
Company News

NeuroVive, Arbutus Biopharma deal

NeuroVive and Arbutus terminated a 2014 deal that granted OnCore Biopharma Inc. exclusive, worldwide rights to NVP018 to treat HBV infection. OnCore merged with Tekmira Pharmaceuticals Corp. in 2015 to form Arbutus. NeuroVive regained all...
BioCentury | Oct 21, 2016
Company News

Arbutus returns cyclophilin inhibitor to NeuroVive

NeuroVive Pharmaceutical AB (SSE:NVP; Pink:NEVPF) regained rights to NVP018 from Arbutus Biopharma Corp. (NASDAQ:ABUS) as the companies terminated a 2014 deal to develop the compound for HBV. The exclusive, worldwide rights to NVP018 were obtained...
BioCentury | Jul 21, 2015
Company News

Tekmira changing name to Arbutus with HBV focus

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) said it will change its name to Arbutus Biopharma Corp., effective Aug. 3, and will focus on developing HBV therapies. It will form a separate business unit for non-HBV therapies, and...
BioCentury | Jun 22, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/19 cls Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Needham Serge Belanger Upgrade Buy (from hold) 54% $20.02 Belanger also set a $27...
BioCentury | Jun 20, 2015
Clinical News

Tekmira falls on Ebola data

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) lost $1.74 (12%) to $13.28 on Friday on news its TKM-Ebola-Guinea was unlikely to show a therapeutic effect in the Phase II RAPIDE trial to treat Ebola virus infection. As a...
BioCentury | Mar 21, 2015
Financial News

Tekmira raises $151.9M in follow-on

Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) raised $151.9 million through the sale of 7.5 million shares at $20.25 in a follow-on underwritten by Leerink; RBC Capital Markets; Nomura; JMP Securities; Wedbush PacGrow; and Lazard. Tekmira proposed the...
BioCentury | Mar 16, 2015
Company News

OnCore Biopharma, Tekmira deal

Tekmira completed its merger with OnCore. The merged company will operate as Tekmira and will continue to trade under the TKMR ticker until a new corporate identity is launched and its ticker symbol is changed...
BioCentury | Jan 19, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/16 cls Depomed Inc. (NASDAQ:DEPO) Roth Capital Partners Scott Henry Upgrade Buy (from neutral) 17% $20.20 Henry also raised his...
Items per page:
1 - 10 of 113